Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of NKTR-214 (BMS-986321) Plus Nivolumab in Advanced Solid Tumors (Japan)
jRCT2080224176Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bempegaldesleukin and nivolumab in Non-hematologic malignancy, sponsored by Bristol Myers Squibb. Primary endpoint: Primary safety and tolerability endpoints. Started Dec 2018; status: completed.
02
Drugs
bempegaldesleukinnivolumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080224176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224176.